Antimicrobial CopperFact 7 of 12
Congressionally funded clinical trials were begun in at three U.S. hospitals in 2007. They are evaluating the efficacy of antimicrobial copper alloys in stemming the infection rates of MRSA, vancomycin-resistant Enterococci (VRE) and Acinetobacter baumannii, of particular concern since the beginning of the Iraq War. Additional studies are seeking to determine copper's efficacy on other potentially lethal microbes, including Klebsiella pneumophila, Legionella pneumophila, Rotavirus, Influenza A, Aspergillus niger, Salmonella enterica, Campylobacter jejuni and others.
